ArticleJournal of clinical medicine2022
Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- S1 guideline sweat gland carcinoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- Microscopically Controlled Surgery in the Management of a Rare Adnexal Neoplasm: A Two-Center Experience of Eccrine Porocarcinoma Treated Through Tubingen Torte Technique.International journal of dermatology · 2026Article
- Epidemiology, treatment patterns, and survival outcomes of porocarcinoma: A population-based analysis.Medicine · 2026Article
- Minor trauma-induced eccrine porocarcinoma of the toe in a patient on long-term carbamazepine: a case report and literature review.Frontiers in oncology · 2026Article
- Eccrine Porocarcinoma in Linear Epidermal Nevus.Clinical, cosmetic and investigational dermatology · 2024Article
- Primary groin porocarcinoma in a 43-year-old man successfully managed by local excision: A case report and literature review.Clinical case reports · 2023Article
- Eccrine Porocarcinoma: A Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- Spiradenocarcinoma: SEER Study of Epidemiology, Survival, and Treatment Options.Journal of clinical medicine · 2023Article
- Diagnosis and Management of Porocarcinoma.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porocarcinoma is a rare malignant adnexal tumor. Little is known about the location of the disease in the head and neck. Our aim is to offer the largest analysis of demographic, pathological, and treatment patterns of head and neck porocarcinoma in comparison with other locations of the neoplasm from an epidemiologically representative cohort.
methodThe Surveillance, Epidemiology, and End Results program of the National Cancer Institute was searched for all cases of porocarcinomas diagnosed between 2000 and 2018. This database is considered representative of the US population. Demographic, pathological, and treatment variables were compared between the head and neck and other regions. Overall and disease-specific survival was calculated and compared between groups.
results563 porocarcinomas were identified, with 172 in the head and neck. The mean age was 66.4 years. Males were more affected in the head and neck. Regional and distant invasion rates were low (2.9 and 2.3%, respectively). Local excision and Mohs surgery were the most frequent therapies. Five-year overall survival was 74.8%. Five-year disease-specific survival was 97%.
conclusionsHead and neck porocarcinoma affects more males than females. Regional or distant metastatic rates are low and overestimated in previous literature. Disease-specific mortality is low. Surgery remains the mainstay of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.